Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis

Paulo D Picon, Suzane Cristina M Pribbernow, Carlos A Prompt, Suzana C Schacher, Veronica V H Antunes, Bianca P Mentz, Fabiane L Oliveira, Celia Mariana B de Souza, Fernando C Schacher, Paulo D Picon, Suzane Cristina M Pribbernow, Carlos A Prompt, Suzana C Schacher, Veronica V H Antunes, Bianca P Mentz, Fabiane L Oliveira, Celia Mariana B de Souza, Fernando C Schacher

Abstract

Objectives: Anemia is a common complication among chronic kidney disease patients on hemodialysis, occurring mostly due to erythropoietin deficiency. This randomized noninferiority trial sought to compare the efficacy and safety of a new epoetin formulation developed by Bio-Manguinhos, a biologics manufacturer affiliated with the Brazilian government, with those of a commercially available product currently used in Brazil (a biosimilar epoetin formulation).

Methods: The sample size needed to enable demonstration of noninferiority with a statistical power of 85% for a between-group difference in hemoglobin levels of no more than 1.5 g/dL was calculated. In total, 74 patients were randomly assigned to receive the epoetin formulation from Bio-Manguinhos (n = 36) or the biosimilar epoetin formulation (n = 38) in a double-blind fashion. The inclusion criteria were current epoetin therapy and stable hemoglobin levels for at least 3 months prior to the study. The primary and secondary outcomes were mean monthly hemoglobin levels and safety, respectively. The dose was calculated according to international criteria and adjusted monthly in both groups according to hemoglobin levels and at the assistant physicians' discretion. Iron storage was estimated at baseline and once monthly. Clinicaltrials.gov: NCT01184495.

Results: The study was conducted for 6 months after randomization. The mean baseline hemoglobin levels were 10.9±1.2 and 10.96±1.2 g/dL (p = 0.89) in the Bio-Manguinhos epoetin and biosimilar epoetin groups, respectively. During the study period, there was no significant change in hemoglobin levels in either group (p = 0.055, ANOVA). The epoetin from Bio-Manguinhos was slightly superior in the last 3 months of follow-up. The adverse event profiles of the two formulations were also similar.

Conclusions: The epoetin formulations tested in this study are equivalent in efficacy and safety.

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1
Figure 1
Flow chart of patient enrollment and follow-up.
Figure 2
Figure 2
Mean hemoglobin levels during the 6-month follow-up in (A) the groups receiving Bio-Manguinhos epoetin (EpoBM) or a commercially available biosimilar formulation (EpoBS) and in (B) diabetic and nondiabetic patients. (C) Mean monthly doses of epoetin alfa in the EpoBM and EpoBS groups.

References

    1. Fishbane S. 8th ed Philadelphia: Saunders; 2007. Hematologic aspects of kidney disease.
    1. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol. 2001;12(11):2465–73.
    1. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14(2 Suppl 1):14–8.
    1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.
    1. Rahman SN, Heifner K, Fadem S, McIovr M, Brenner R, Powers K, et al. Chicago: National Kidney Foundation (NKF); 2002. HRQOL improvements in anemic CKD patients treated with Darbepoetin Alfa (Aranesp TM.
    1. Brazil. Ministério da Saúde - Secretaria de Atenção à Saúde. Anemia em pacientes com insuficiência renal crônica. In: Picon P D, Gadelha M I P, Beltrame A, editors. Protocolos clínicos e diretrizes terapêuticas. Brasília: Ministério da Saúde; 2002.
    1. Pribbernow SCM, Vinhas de Souza M, Prompt CA, Picon PD. Anemia e uso de eritropoetina nos pacientes em hemodiálise no Hospital de Clínicas de Porto Alegre. Rev HCPA. 2006;26(3):5–11.
    1. Sesso Rde C, Lopes AA, Thome FS, Lugon JR, Watanabe Y, Santos DR. [Chronic dialysis in Brazil: report of the Brazilian dialysis census, 2011] J Bras Nefrol. 2012;34(3):272–7.
    1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297(15):1667–74.
    1. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada. 2004 RDC N°. 154, de 15 de junho de 2004.
    1. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145.
    1. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.
    1. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med. 2009;169(12):1104–12.
    1. Food and Drug Administration (FDA) Erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)] [Internet]. 2006 [cited 2010 June 26]. Available from: .
    1. Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, et al. Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents. Kidney Int Suppl. 2008;110:S12–8.
    1. Ammirati AL, Watanabe R, Aoqui C, Draibe SA, Carvalho AB, Abensur H, et al. Variação dos níveis de hemoglobina de pacientes em hemodiálise tratados com eritropoetina: uma experiência brasileira. Rev Assoc Med Bras. 2010;56(2):209–13.
    1. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64(4):1514–21.
    1. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1(6):1205–10.
    1. Lacson E, Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41(1):111–24.
    1. Costongs GM, Janson PC, Bas BM, Hermans J, van Wersch JW, Brombacher PJ. Short-term and long-term intra-individual variations and critical differences of clinical chemical laboratory parameters. J Clin Chem Clin Biochem. 1985;23(1):7–16.
    1. Dot D, Miro J, Fuentes-Arderiu X. Within-subject biological variation of hematological quantities and analytical goals. Arch Pathol Lab Med. 1992;116(8):825–6.
    1. Ross DW, Ayscue LH, Watson J, Bentley SA. Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation. Am J Clin Pathol. 1988;90(3):262–7.
    1. Cheung AK, Daugirdas J, Dwyer J. Seasonal variations (SV) in clinical and laboratory parameters in hemodialysis patients. J Am Soc Nephrol. 1999;10:236A.
    1. Breiterman-White R. Hemoglobin variability: management inevitable changes in clinical status. Nephrol Nurs J. 2005;32:549–52.
    1. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68(3):1337–43.
    1. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant. 2007;22(8):2129–32.
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9.
    1. United States Renal Data System (USRDS) Bethesda: National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases; 2008. Morbidity and mortality: all-cause hospitalization. Annual data report 2008.
    1. Schwab SJ. Hemodialysis vascular access. In: Jacobson H R, Strieker G E, Klahr S, editors. The principles and pratices of nephrology. Philadelphia: Decker; 1991. pp. p. 766–72.
    1. Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2012;55(3):849–55.
    1. Ayez N, Fioole B, Aarts RA, van den Dorpel MA, Akkersdijk GP, Dinkelman MK, et al. Secondary interventions in patients with autologous arteriovenous fistulas strongly improve patency rates. J Vasc Surg. 2011;54(4):1095–9.
    1. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vasc Surg. 1997;26(6):1009–19.
    1. Berkoben MS, Schwab SJ. Vascular access for hemodialyis. In: Nissenson A R, Fine R N, editors. Clinical dialysis. 4th ed. New York: Mcgraw-Hill; 2005. pp. p. 27–45.
    1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.
    1. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58(3):1325–35.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren